Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, RNA modifications and cancer, and Lung Cancer Research Studies.
Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis
Low tumour interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study. Authors´reply
TCF21 Deficiency Induces Fibroblast Apoptosis and Promotes Fibrotic Changes in the Human Lung Mesenchyme
Author Reply to Peer Reviews of Epigenetic dysregulation of IRF9 drives excessive interferon signalling in COPD
Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study
Epitranscriptomic rRNA fingerprinting reveals tissue-of-origin and tumor-specific signatures
PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine Neoplasms
Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients
The pregnancy-associated protein glycodelin as a potential sex-specific target for resistance to immunotherapy in non-small cell lung cancer
Low tumor interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study
Epigenetic deregulation in AT2 cells impairs alveolar regeneration in COPD.
High‐resolution transcriptomic and epigenetic profiling identifies novel regulators of COPD
Early Detection of Lung Cancer Using Small RNAs
Preliminary results from the EMoLung clinical study showing early lung cancer detection by the LC score
Epigenetic deregulation of IFN and WNT pathways in AT2 cells impairs alveolar regeneration (in COPD)
Cancer-associated fibroblasts promote drug resistance in <i>ALK</i> -driven lung adenocarcinoma cells by upregulating lipid biosynthesis
Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy
Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
Lung Adenocarcinoma Cell Sensitivity to Chemotherapies: A Spotlight on Lipid Droplets and SREBF1 Gene
Intratumoral Heterogeneity and Immune Modulation in Lung Adenocarcinoma in Female Smokers and Never Smokers
Identification of NHLRC1 as a Novel AKT Activator from a Lung Cancer Epigenome-Wide Association Study (EWAS)
Cellular dissociation grading on biopsies of pulmonary squamous cell carcinoma provides prognostic information across all stages and is congruent with resection specimen grading
High-resolution transcriptomic and epigenetic profiling identifies novel regulators of COPD phenotypes in human lung fibroblasts
High-resolution transcriptomic and epigenetic profiling across disease stages identifies novel regulators of COPD phenotypes.
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
Sarcopenia on preoperative chest computed tomography predicts cancer‐specific and all‐cause mortality following pneumonectomy for lung cancer: A multicenter analysis